[Production, identification and redirected cytotoxicity of CD3/CD19 bispecific monoclonal antibody].
OBJECTIVE
To prepare CD3/CD19 bispecific monoclonal antibody (BsAb) and study its biological effects.


METHODS
The CD3/CD19 BsAb was prepared by using hybri-hybridoma technique. The presence of BsAb was demonstrated by double-isotype ELISA and cell conjugate assay.


RESULTS
We obtained three strains of CD3/CD19 quadromas, including a stable one. 51Cr release assay showed that CD3/CD19 supernatants, CD3/CD19 purified antibody and CD3/CD19 chemical heterocongjugate greatly enhanced the cytotoxic activity of CD3 AK cells against Nalm-6 cells (P < 0.05-0.001).


CONCLUSIONS
The CD3/CD19 BsAb we prepared was efficient in redirecting activated T cells against target tumor cells. This indicates that the CD3/CD19 BsAb has potential value of clinical use.
Chen
X
X
Institute of Hematology, CAMS and PUMC, Tianjin 300020.
Shen
D
D
Sun
T
T
Bai
J
J
Huang
L
L
D000818:Animals; D018033:Antibodies, Bispecific / Q000096:biosynthesis*; D000911:Antibodies, Monoclonal / Q000276:immunology*; D018941:Antigens, CD19 / Q000276:immunology*; D017252:CD3 Complex / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D006801:Humans; D006825:Hybridomas / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D016393:Lymphoma, B-Cell / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D014407:Tumor Cells, Cultured
D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D018941:Antigens, CD19; D017252:CD3 Complex